What’s new

• Board meeting set for July 11, 2026 to discuss acquisition of Sushodha Institute of Gastroenterology.
• Also up for approval: material related party transactions with newly appointed Executive Director Bidari Kotresh Anilkumar.
• Potential issuance of equity on preferential basis for a share swap and a rights issue to existing shareholders.

Why it matters

For a nano-cap with zero debt and rapid growth from a tiny base, an acquisition and capital raise could reshape the business. But the intimation carries no numbers, no deal size, no pricing, no commitment. Today it's just a teaser.

What we’re watching

• Financial details post-meeting: acquisition value, share swap ratio, and rights issue size.
• Whether the acquisition fits Arvaya's existing trading or healthcare operations.
• Any change in promoter holding from preferential allotment.

The full read

Arvaya Healthcare's board meets on July 11, 2026 to consider an acquisition, related party transactions, and capital raising. The target is Sushodha Institute of Gastroenterology. Also on the table: a preferential share swap for equity and a rights issue. The company is a nano-cap with a ₹322 cr market cap, zero debt, and rapid growth from a tiny base. But today's filing contains no financials. No deal size, no pricing, no binding terms. It's a notice of intention, not a done deal. With no debt and a small scale, the acquisition and fundraise could dramatically change Arvaya's business if the board approves concrete terms. That's a big 'if' until the July 11 meeting produces numbers.

Primary source: BSE · NSE